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ABSTRAK 
 
 
PENGESANAN MUTASI DI PDGFRA PADA EKSON 12 DAN 18 DI KALANGAN 
PESAKIT-PESAKIT LEUKEMIA MEILOID KRONIK YANG TELAH DIRAWAT 
DENGAN IMATINIB MESYLATE 
 
 
Rintangan terhadap rawatan imatinib mesylate (IM) merupakan cabaran baru dan utama 
dalam merawat pesakit leukemia mieloid kronik (CML). Rintangan terhadap IM boleh 
dibahagikan kepada dua laluan iaitu laluan yang bergantung kepada BCR-ABL dan laluan 
yang tidak bergantung kepada BCR-ABL. Mekanisma yang berada di laluan yang tidak 
bergantung kepada BCR-ABL diuji dalam projek ini; yang melibatkan mutasi di PDGFRA 
sebagai mekanisma rintangan pada pesakit -pesakit CML positif Philadelphia yang dirawat 
dengan IM. PDGFRA adalah tergolong dalam kumpulan tyrosine kinase Kelas III; bukan 
sahaja menyumbang kepada pembentukan haematopoiesis tetapi juga telah dikaitkan dengan 
kanser. Mutasi PDGFRA membawa kepada pengaktifan kendirian menyebabkan penambahan 
spontan sel. Analisis penjujukan PCR-DNA telah dijalankan untuk mengesan mutasi 
PDGFRA pada ekson 12 dan 18. Lapan puluh enam pesakit CML positif Philadelphia dari 
lima hospital rujukan di seluruh Semenanjung Malaysia yang berada dalam fasa penyakit 
yang berbeza dirawat dengan  IM dari tahun 2010 sehingga 2013 telah dinilai (pesakit yang 
xv 
 
responsif, n= 43 ; pesakit yang rintang, n=43). Sampel pesakit-pesakit ini diperoleh daripada  
kajian projek berkaitan CML terdahulu. Daripada kesemua pesakit-pesakit dalam kumpulan 
yang rintang terhadap IM, 32 pesakit berada dalam fasa CML kronik; 7 pesakit dalam fasa 
percepatan CML; dan 4 pesakit dalam fasa blastik CML. Pesakit yang berumur dari 20 
hingga 73 tahun telah dikategorikan ke dalam pelbagai kumpulan umur dari pesakit yang 
lebih muda (umur yang lebih muda daripada 60 tahun) sehingga pesakit yang lebih tua (umur 
60 tahun atau lebih tua). Amplifikasi tindak balas rantai polimerase  di lokasi yang terpilih 
telah dijalankan iaitu pada ekson 12 dan 18 diikuti oleh saringan mutasi oleh penjujukan 
langsung untuk kesemua sampel. Keputusan penjujukan telah sejajar dengan menggunakan 
Asas Tempatan Penjajaran Search Tool (BLAST) untuk membandingkan urutan pertanyaan 
dengan rujukan urutan. Kebanyakan pesakit yang tidak memberi respon terhadap rawatan IM 
adalah wanita. Median umur ialah 43 tahun. Sebanyak 74 % daripada pesakit CML yang 
tidak memberi respon terhadap IM berada dalam fasa kronik. Namun begitu, tiada pesakit 
CML dalam kajian ini menunjukkan mempunyai mutasi pada ekson potensi; ekson 12 dan 18 
dalam PDGFRA. Kajian ini menunjukkan wanita mempunyai kekerapan rintang yang lebih 
tinggi terhadap rawatan IM dan berlaku terutamanya di kalangan pesakit yang lebih muda. 
Ketiadaan mutasi PDGFRA di ekson 12 dan 18 kemungkinan kerana mutasi berada di lokasi-
lokasi lain pada gen ini. Majoriti sampel kajian adalah dari pesakit fasa kronik mungkin 
menyumbang kepada mutasi negatif. Kajian pada masa depan haruslah berpandukan ke arah 
mencari ekson-ekson lain yang berpotensi dengan memilih lebih pesakit dalam peringkat 
berbahaya untuk meperolehi kekerapan mutasi yang lebih tinggi. Kajian klinikal dan 
tambahan ‘pathogenetic’ diperlukan untuk memahami kaitan antara PDGFRA dan IM rintang 
CML. 
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ABSTRACT 
 
 
DETECTION OF PDGFRA MUTATIONS AT EXONS 12 AND 18 AMONG CHRONIC 
MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE 
 
 
Imatinib mesylate (IM) resistance is an emerging and major challenge in the treatment of 
patients with chronic myeloid leukaemia (CML). Resistance toward IM can be divided into 
BCR-ABL dependent pathways and BCR-ABL independent pathway. In this study, the BCR-
ABL independent pathway was investigated; the involvement of PDGFRA mutation as a 
mechanism of resistance in Philadelphia positive CML patients treated with IM. The 
PDGFRA belongs to the tyrosine kinase Class III; not only contribute to haematopoiesis 
development but also has been implicated in cancers. Mutation of PDGFRA leads to 
constitutive activation causing spontaneous proliferation. PCR-DNA sequencing analyses 
were carried out to detect exons 12 and 18 of PDGFRA mutations. Eighty-six patients from 
five tertiary hospitals around peninsular Malaysia in different phases of Philadelphia-positive 
CML who were treated with IM from 2010 until 2013 were evaluated (IM-responsive 
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patients, n= 43; IM-resistant patients, n=43). These samples were archived from the earlier 
CML project. Of all the patients in resistant group, 32 patients in chronic phase CML; 7 
patients in accelerated phase CML; and 4 patients in blastic phase CML. Patients aged from 
20 until 73 years were categorized into a range of age group from younger patients (age 
younger than 60 years) till older patients (age 60 years or older). Polymerase chain reaction 
amplifications were performed on the selected hotspots; exons 12 and exon 18 followed by 
screening for mutations by direct sequencing in 43 resistant and 43 responsive CML samples. 
Sequencing results were aligned by using Basic Local Alignment Search Tool (BLAST) to 
compare a query sequence with a reference sequences. Resistant patients predominate by 
female and the median age was 43. There were 74% of the resistant CML in chronic phase. 
None of the CML patients in this study exhibit any mutation on the hotspot exons 12 and 18 
in PDGFRA. This study shows higher frequency of IM resistance notable in female and 
occurring mainly in younger age population. The absence of PDGFRA mutation at exons 12 
and 18 may suggest that other regions of this gene could be involved. Majority of the study 
samples were from chronic phase patients might contribute to the negative mutation finding. 
Future study should be directed towards finding more potential exons by selecting more 
patients in advance stage in order to yield higher mutation frequency. Additional clinical and 
pathogenetic studies are needed to understand the association between PDGFRA and IM-
resistant CML.  
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LITERATURE REVIEW 
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1.1   Introduction 
1.1.1   Blood malignancies 
 
Blood malignancies or haematological neoplasms are comparatively common, 
accounting for around 9% of all cancers and being the fourth most frequently diagnosed 
cancer in both men (after prostate, lung, and colorectum) and women (after breast, lung, and 
colorectum) in economically developed regions of the world (Smith et al., 2011). 
 
These neoplasms are forms of cancer that begin in the cells of blood-forming tissue, such 
as the bone marrow, or in the cells of the immune system. It may derive from either of the 
two major blood cell lineages: myeloid and lymphoid cell lines. The myeloid cell line 
normally produces granulocytes, erythrocytes, thrombocytes, macrophages and mast cells; 
the lymphoid cell line produces B, T, natural killer (NK) and plasma cells. Malignancies such 
as lymphomas, lymphocytic leukemias, and myeloma are from the lymphoid line, while acute 
and chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS) and 
myeloproliferative neoplasms (MPNs) are myeloid in origin.   
Unlike many other cancers, haematological neoplasms are diagnosed using multiple 
parameters; such as morphology, cytochemistry, immunophenotype, genetics and clinical 
features in order to define clinically significant disease entities. The current classification 
system was established by the World Health Organisation (WHO) in 2001 and more recently 
modified in 2008 to refine the diagnosis (Swerdllow et al., 2008). This classification stratifies 
neoplasms according to their lineage (myeloid, lymphoid, histiocytic/dendritic) and 
distinguishes neoplasms of precursor cells from those comprised of functionally mature cells. 
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Brief overviews on lymphoid neoplasms (LN), LNs are derived from the clonal 
expansion and proliferation of B- and T-lymphocytes. They encompass a heterogeneous 
group of lymphomas and leukemias including B-cell, T-cell, and NK-cell disorders. Whereas 
for myeloid neoplasm (MNs), five major subgroups of MNs are recognized based mainly on 
their degree of maturation and biologic properties: MPNs which are comprised primarily of 
mature cells with effective proliferation; myeloid (and lymphoid) neoplasms with 
eosinophilia and abnormalities of platelet-derived growth factor alpha gene (PDGFRA), 
platelet-derived growth factor beta gene (PDGFRB) and fibroblast growth factor receptor 1 
gene (FGFR1), defined largely by the finding of significant eosinophilia and specific genetic 
abnormalities; MDS/MPN comprised mainly of mature cells with both effective and 
ineffective proliferation of various lineages; MDS, in which immature and mature cells are 
found with abnormal, dysplastic and ineffective maturation, and acute myeloid leukemia  
(AML), comprised of precursor cells with impaired maturation (Vardiman, 2010).   
 
According to the revised WHO Classification Scheme in year 2008, CML was assigned 
under MPN category together with polycythemia vera, essential thrombocytopenia, primary 
myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia  (not otherwise 
specified), mast cell disease and MPN unclassifiable (Tefferi et al., 2009). 
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      1.1.2         Chronic Myeloid Leukemia and its genetic basis 
 
CML is characterized by uncontrolled expansion of myeloid cells particularly the 
granulocytic cell line without the loss of their capacity to differentiate. The incidence of CML  
were 1 to 2 cases per 100,000 adults, and accounts for 15% of newly diagnosed cases 
of leukemia in adults (Jemal et al., 2010) .  
 
This is the first human cancer in which a consistent genetic abnormality was 
demonstrated to cause the disease (Sherbenou and Druker, 2007).  CML is associated with 
the presence of the Philadelphia (Ph) chromosome leading to a BCR-ABL fusion. The Ph 
chromosome is the result of a balanced t(9;22)(q34;q11) translocation, and is observed in 
more than 90% of CML cases, with variant Ph translocations being observed in the remainder 
(O'Brien et al., 1997). 
 
This oncogenic fusion BCR-ABL, produce a constitutively active tyrosine kinase and 
is important in the pathogenesis and expression of CML. CML ensues when an abnormal 
pluripotent hematopoietic progenitor cell initiates excessive production of granulocytes, 
primarily in the bone marrow but also manifested in extramedullary sites (eg. spleen, liver). 
Although granulocyte production predominates, the neoplastic clones include red blood cells, 
megakaryocytes, monocytes, and even some T and B cells.  
 
With a rapid expansion of granulocytes and advance disease ensues, metastasis may 
come to the picture which later progress to organ failure and death. Epidemiologic data 
indicates that almost 5000 new cases are reported every year and 10% of these patients 
eventually succumb to the disease (An et al., 2010). 
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           1.1.2.1     Classification and clinical phases 
 
CML is classified into three phases based on clinical features and laboratory findings; 
chronic, accelerated, and blast phase. Approximately 90% of patients are diagnosed in the 
chronic phase (CP) and, historically have a median survival close to 5 years (Cortes et al., 
2006). In the CP of disease, mature cells proliferate exceeding the normal rate. Patients at this 
phase are asymptomatic but CML progression is insidious, with a nonspecific “benign” stage 
(malaise, anorexia, weight loss). Unless the disease is treated, CML evolves from a CP 
characterized by the Ph chromosome as the sole genetic abnormality into blast crisis or blast 
phase (BP), which is often associated with additional chromosomal and molecular secondary 
changes (Calabretta and Perrotti, 2004). This is considered as a natural progression of 
disease. 
 
During this phase, patient manifests ominous signs such as splenomegaly, pallor, easy 
bruising and bleeding, fever, lymphadenopathy and skin changes. Two-thirds of patients who 
develop BP go through an intermediate accelerated phase (AP) with median survival of 
patient in AP is 1 to 2 years (Cortes et al., 2006). The BP is the last stage or blast crisis where 
immature cells rapidly proliferate and more or less resembling the acute leukemia and at this 
point of progression the patient deteriorates considerably fast leading to mortality.  
 
 The term “advanced phase” is sometimes used to describe both the AP and BP. There 
are two distinct types of blast phases defined by the types of blast cells present. In most 
patients the blast cells (immature white cells) resemble those seen in AML, whereas in about 
a quarter of patients, the blast cells look more like those seen in acute lymphoblastic 
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leukaemia (ALL). This latter form of the disease is known as lymphoid blast crisis and tends 
to have a poorer response to treatment. 
 
CML cases were account for 20% of all adult leukemias worldwide (Singer et al., 
2011). It typically affects middle-aged individuals. Uncommonly, the disease occurs in 
younger individuals. Younger patients may present with a more aggressive form of CML, 
such as in accelerated phase or blast crisis. Uncommonly, CML may appear as a disease of 
new onset in elderly individuals. 
 
           1.1.2.2     Treatment and management 
 
The treatment of CML and the survival rate largely depends on the stage where the 
diagnosis is made. The time of diagnosis does contribute to the prognosis of the patient with 
this disease and directly related to the outcome of the patient as in chronic stage the 
progression can be stopped. Most of the patients seen in AP transition to blast crisis, it is 
imminent and the outcome is poor. 
 
The elucidation of the molecular pathogenesis of CML led to the development of its 
targeted therapy. This was unprecedented until CML was regarded as a life-threatening 
disease with a median life expectancy of around six to seven years with the only exception 
being the minority of patients who could receive a compatible stem cell transplant. Previous 
years, cytotoxic drugs are the main modality as therapeutic option for CML before the 
discovery of BCR-ABL. Nevertheless, effective chemotherapy does not change the natural 
history of CML thus most patients would ultimately progress to blast phase.  
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 The drugs that have been used by clinician to treat CML were hydroxyurea, busulfan 
and interferon. Hydroxyurea is the easiest therapy to be managed and has the fewest adverse 
effects. Unfortunately cytogenetic responses are rare and the onset to blast crisis is not 
delayed, with transformation occurring within a median of 4 to 6 years (Salesse and 
Verfaillie, 2002).  
 
Busulfan has been known to cause unexpected general myelosuppression, and 
interferon causes a flu-like syndrome that frequently is unacceptable to patients. In contrary, 
these therapies alleviate the distressing splenomegaly and adenopathy and help in control of 
the tumor burden to reduce the incidence of tumor lysis and gout.  Too unfortunate, none of 
these therapies prolongs median survival more than 1 year compared with untreated patients; 
thus, reduction in symptoms is the major goal, and therapy is not continued when patients 
have significant toxic symptoms (Porter et al., 2006). 
           1.1.2.2 (a)     Imatinib mesylate (IM)  
 
 
A very essential lesson learned from IM is that the discovery of the primary genetic 
abnormality in a malignancy together with the development of an agent that targets that 
abnormality, can lead to therapeutic success. IM is a 2-phenylaminopyrimidine derivative 
developed originally as a general tyrosine kinase inhibitor (TKI) that was modified 
chemically so as to compete with adenosine triphosphate (ATP) for the ATP-binding site or 
P-loop in the ABL protein and thereby block the deregulated enzymatic function of the BCR-
ABL oncoprotein (Goldman, 2009).  
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This BCR-ABL TKI (Glivec®, formerly STI571, Novartis Pharma AG, Basel, 
Switzerland) prevent tyrosine kinase turning into its active form thus inhibits cellular 
proliferation without the induction of apoptosis. An in vitro study reported that IM produced 
a 92% to 98% decrease in CML colony growth without significantly inhibiting normal colony 
growth (An et al., 2010).  It has been proven to produces complete hematologic and 
cytogenetic responses in a substantial percentage of CML patients and it is effective in CP, 
AP and blast crisis, with lower response rates in patients with more advanced disease 
(Buchdunger et al., 2002). 
 
 The clinical use of IM has resulted in a significantly improved prognosis, response 
rate, overall survival, and patient outcome in CML patients compared to previous therapeutic 
regimens by busulfan, hydroxyurea and interferon. Results from the  International 
Randomized Study of Interferon and STI571 (IRIS) trial in newly diagnosed CML-
CP showed that, cumulatively, 98% of patients who received IM as initial therapy achieved a 
complete haematological remission and 87% achieved a complete cytogenetic remission 
(Assouline and Lipton, 2011). The above phases of disease progression have changed 
dramatically in the IM era. For most patients, the CP lasts at least ten years, possibly much 
longer, and only a minority of patients who start treatment in the CP fail to respond well to 
IM.  
 
Relapses have been common in blast crisis associated with reactivation of BCR-ABL 
kinase activity.  Approximately 33% of patients with CML treated with IM do not achieve a 
complete cytogenetic response (CCyR), while others have drug resistance or cannot tolerate 
drug-related toxicities (Bixby and Talpaz, 2009; Hochhaus et al., 2009). Two categories of 
IM resistance have been characterized: primary resistance is the failure to achieve any of the 
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landmark responses established by the European LeukemiaNet (ELN) (Baccarani et al., 
2006). Primary resistance also known as intrinsic resistance can be further divided into 
primary hematologic resistance and primary cytogenetic resistance. Primary hematologic 
resistance accounts for 2 to 4% of cases who fail to normalize peripheral counts within 3 to 6 
months of initiation of treatment whereas primary cytogenetic resistance, which is more 
common, observed in approximately 15 to 25% of patients who fail to achieve any level of 
cytogenetic response (CyR) at 6 months, a major CyR (MCyR) at 12 months or a complete 
CyR (CCyR) at 18 months (Shah, 2007). Secondary resistance occurs in those who have 
previously achieved and subsequently lost their response in accordance with the guideline 
(Bhamidipati et al., 2013). The mechanisms of resistance to IM can be either BCR-ABL 
dependent (gene amplification or point mutations) or BCR-ABL independent (La Rosée and 
Deininger, 2010). The present study was designed to investigate the mechanisms of resistance 
involving BCR-ABL independent pathway. 
 
The use of pre-imatinib-era treatment strategies such as hydroxyurea, busulfan or 
interferon by some physicians as salvage treatment after IM failure and unsuitability of stem 
cell transplantation still occurs despite the growing availability of newer TKIs (Rohrbacher 
and Hasford, 2009). This has reflected that not all CML cases are caused by solely Ph 
chromosome translocation, some other molecular mechanism must have contributed to its 
pathogenesis and disease progression making treatment with the most effective drug turned 
into a complicated non effective effort. 
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        1.1.3   Role of tyrosine kinases (TKs) in cancer 
 
TKs are a subclass of protein kinase. Protein TKs are enzymes that transfer phosphate 
groups to tyrosine residues on protein substrates. Phosphorylation of proteins cause changes 
in their function and/or enzymatic activity resulting in specific biological responses (Gocek et 
al., 2014). It functions as a switch in many cellular functions and is the key role in diverse 
biological processes like growth, differentiation, metabolism and apoptosis in response to 
external and internal stimuli.  
 
As the sequencing of the human genome is completed by the Human Genome Project, 
90 unique kinase genes can be identified.  Of the 90 TKs, 58 are receptor type, receptor 
tyrosine kinases (RTKs), distributed into 20 subfamilies and 32 non-receptor tyrosine kinases 
(NRTKs)  can be placed in 10 subfamilies (Robinson et al., 2000) . RTKs are part of the 
larger family of protein tyrosine kinases which contain a transmembrane domain, whereas the 
NRTKs do not possess transmembrane domains.  Haematopoiesis is controlled by a number 
of growth factors and cytokines, a number of which act through binding to high-affinity 
RTKs (Reilly, 2003). RTKs are activated by ligand binding to the extracellular domain 
followed by dimerization of receptors facilitating trans-phosphorylation in the cytoplasmic 
domain (Paul and Mukhopadhyay, 2004). The most important downstream signalling 
cascades activated by RTKs include the Ras–extracellular regulated kinase (ERK)–mitogen 
activated protein kinase (MAPK) pathways, the phosphoinositide 3-kinase (PI 3-kinase)–Akt 
and the Janus kinase and Signal Transducer and Activator of Transcription (JAK/STAT) 
pathway leading either to a complex  activation or repression of various subsets of genes for 
running biological functions. 
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TKs have been implicated in the pathophysiology of cancer. Though their activity is 
tightly regulated in normal cells, deregulation may result in deregulated TK activity with 
constitutive or strongly enhanced signalling capacity, leading to malignancy. The most 
important mechanisms leading to constitutive RTK signalling include: overexpression and/or 
gene amplification of RTKs, genetic alterations such as deletions and mutations within the 
extracellular domain as well as alterations of the catalytic site, or autocrine–paracrine 
stimulation through aberrant growth factor loops (Zwick et al., 2002). 
 
 In CML, the important and related TK gene involves directly is ABL which is 
classified under NRTK whereas the gene in this study is PDGFRA which is under class III 
RTK. Class III RTK is arguably one of the most intriguing RTK classes in terms of 
evolutionary, functional and clinical considerations (Grassot et al., 2006; Verstraete and 
Savvides, 2012). Characterized by present of five immunoglobulin-like domains in the 
extracellular ligand-binding region, this class of RTK has grown to harbour another four 
members include PDGFRB (platelet-derived growth factor receptor beta), c-KIT (cellular 
component-stem cell factor receptor, CD117), FLT3 (FMS-like tyrosine kinase, CD135) and 
c-FMS (colony-stimulating factor-1 receptor).  
 
         1.1.4   Platelet derived growth factor receptor alpha (PDGFRA) 
 
 Platelet-derived growth factor receptors (PDGFRs) and their ligands, platelet-derived 
growth factor (PDGFs) play critical roles in mesenchymal cell migration and proliferation 
(Jones and Cross, 2004). These growth factors are mitogens for cells of mesenchymal origin.  
Two types of PDGFRs have been identified: alpha-type and beta-type.  
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The PDGFRA belongs to the sub-family of proteins within the family of receptor 
tyrosine kinases which is class III. The structure of the PDGFA receptor comprises an 
extracellular domain (the portion extending outside of the cell membrane), a juxtamembrane 
domain (the portion just inside of the cell membrane), and two sections inside the cell known 
as the two catalytic parts of the kinase domain. (Refer Figure 1.1) One part of the kinase 
domain is essential for the binding of ATP and the other part is needed for the transfer of a 
phosphate group that leads to kinase activation. PDGFRA can forms homo- or heterodimers 
by binding to the endogenous PDGFR ligands; PDGF-A, -B, -C and –D. Upon binding of the 
receptor and its ligand, this will induce receptor dimerization and transphosphorylation at 
specific tyrosine residues thus activate the intracellular kinase activity, initiating intracellular 
signalling.  
 
PDGFRA is the approved gene symbol according to the HUGO Gene Nomenclature 
Committee (HGNC). The other names that also encodes for this gene were CD140A and 
PDGFR2.  The full length PDGFRA is encoded by a 6.4 kb transcript but there is also 
evidence for a 3.0 kb transcript as a result of alternative splicing, potentially encoding a 
truncated, dominant-negative receptor isoform (Mosselman et al., 1996). Both these 
transcripts are generated from a promoter upstream of exon 1 (P1 promoter).  This gene can 
be found at chromosome 4 located at 4q12. This gene has 23 exons and 1089 amino acid 
residues.  
 
PDGFRA and other members in the same class were originally grouped under the 
PDGFR family. They are crucially important in the development and homeostasis of the 
cellular repertoire of the haematopoietic and immune systems but both PDGFR subtypes have 
primary roles in mesenchymal processes such as angiogenesis, fibroblast proliferation, bone 
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formation and tissue repair (Verstraete and Savvides, 2012). Recently in Frenette`s group, 
PDGFRA was shown to be one of the markers of hematopoiesis-supporting nestin- 
expressing multipotent stromal cells in the human system (Pinho et al., 2013).  
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Figure 1.1   Structure of PDGFA receptor is comprised of five extracellular 
immunoglobulin- like  domains, a juxtamembrane domain and two catalytic part of 
kinase domains. (Adapted from Pierotti et.al., 2011). (Pierotti et al., 2011) 
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             1.1.4.1   IM resistance in PDGFRA mutation 
 
The expanding understanding of the basis of IM-mediated tyrosine kinase inhibition 
has revealed a spectrum of potential new antitumor applications apart from its excellence 
capability in the treatment of CML. IM  is a potent inhibitor of both receptors, PDGFRA and 
PDGFRB and has shown activity in vivo against platelet-derived growth factor (PDGF)-
driven tumor models including gastrointestinal stromal tumours (GISTs), glioblastoma, 
dermatofibrosarcoma protuberans and chronic myelomonocytic leukemia (Buchdunger et al., 
2002) . 
GIST commonly harbours oncogenic mutations of the KIT or PDGFRA kinases, 
which are targets for IM. (Heinrich et al., 2003b; Hirota et al., 2003). The PDGFRA  is very 
similar to the KIT  (both are the member of same RTK family) and  the genes coding 
for KIT and PDGFA receptors are found in close proximity on chromosome 4q12 (Spritz et 
al., 1994). Mutations of PDGFRA lead to independent activation of the receptor in the 
absence of ligand; this is called constitutive activation (Heinrich et al., 2003b). This means 
the cell is carrying out spontaneous proliferation without the normal signalling ligand telling 
the cell to grow. The result is uncontrolled growth of a tumour. The “downstream” pathways 
that come into play in the cell following activation of mutant PDGFRA are thought to be 
fairly similar with KIT in GIST (Duensing et al., 2004). However, different sets of genes are 
expressed depending on which gene is mutant (Antonescu et al., 2004; Subramanian et al., 
2004; Kang et al., 2006). 
 Approximately 80% of GISTs express the mutated receptor tyrosine kinase KIT. 
However about 8% of GISTs have a normal KIT (wildtype) but 5% show mutations in the 
gene for PDGFRA (Joensuu, 2006).  PDGFRA mutations in GIST have been found in exons 
12, 14 and 18 (corresponding to exons 11, 13 and 17 of KIT) (Refer Figure 1.2).  
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Figure 1.2     Diagrammatic representation of the structure of the KIT and PDGFRA showing the 
corresponding identified mutations of both genes in GIST. The most frequent activating mutations 
of the homologous PDGFRA kinase in patients with GIST are in exon 18, such as the D842V 
substituition that shows resistance to IM. Mutation in the juxtamembrane domain (exon 12; 
V561D most common) and exon 14 of tyrosine kinase 1 (TK1) domain (e.g., N659K) are less 
common. (Adapted from Heinrich,2006). (Heinrich, 2006) Molecular basis for 
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According to a study done by Corless et.al., the leading mutation of all GIST caused by 
PDGFRA activating mutations, is found on exon 18 which  accounted for 89.6% followed by 
9.3% in exon 12 (Corless et al., 2005). Of all the mutations in exon 18 of PDGFRA, the 
D842V mutation is the most common and has been proven to be IM resistant (Heinrich et al., 
2003a). The similar mutational status might also happen in CML that leads to the resistant to 
the treatment given. 
 
 
1.2      Rationale of the study 
 
This study may generate new data on potential involvement of PDGFRA mutations 
among CML patients treated with IM. Since many data from previous studies have implicated 
a subset of PDGFRA mutation has caused the IM resistance in GIST cases, this has instigate 
the curiosity of knowing whether the same mechanism play a role in the resistance cases of 
IM in CML patients. Thus in this research, since the most common sites of mutations in GIST 
cases which resistant to IM occur at exons 12 and 18,  we adapted the facts as hypotheses to 
be tested in CML cases treated with IM that manifest similar behaviour. 
 
Identifying key components involved in the CML pathogenesis may lead to the 
exploration of new approaches that might eventually overcome the resistance of this 
particular TKI. This may shed some light on how to treat resistance cases and might also 
reflect a better prognosis of CML patients. 
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1.3   Objectives of the study 
 
       1.3.1  General objective 
 
To determine whether there are PDGFRA mutations in exons 12 and exon 18 in CML 
patients and any association with the resistance the patients experience on the treatment of 
IM. 
 
 
       1.3.2    Specific objectives 
 
 To perform the PCR amplification of selected hot spots (exons 12 and 18) of 
PDGFRA. 
 To sequence the PCR product to determine the presence of any PDGFRA mutations. 
 To relate frequency of any PDGFRA mutations with CML status in association with 
IM treatment. 
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MATERIALS AND METHODS 
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2.1 Study design and study subject 
 
This is a comparative cross-sectional study conducted in the Human Genome Centre, 
School of Medical Sciences, Universiti Sains Malaysia, Health Campus. This study was 
approved by the Research Committee, School of Medical Sciences, Universiti Sains Malaysia 
(Reference no:USMKK/PPP/JEPem(221.3[9]). The blood samples used in this study were 
archival from the previous study entitled “Influence of TERT gene copy number status and its 
mRNA expression level in association with telomerase activity in Chronic Myeloid Leukemia 
patients resistance to Imatinib Mesylate treatment”.  
 
Total of 86 samples from two different groups of patients enrolled by random 
sampling included in this study which comprised of 43 samples from each group; resistant 
group and responsive group. The samples were obtained from patients who were clinically 
confirmed diagnosis of CML.  
 
 
2.2 Sample size 
 
Power and sample size (PS) software was employed to calculate sample size. A study 
of independent cases and controls with 1 control(s) per case was designed.  Prior data from a 
study done in a group of patients with rearrangement of PDGFRA treated with IM indicate 
that the failure rate among controls is 0.5 (Cools et al., 2003). If the true failure rate for 
experimental subjects is 0.214, we will need to study 43 experimental subjects and 43 control 
subject (which in this situation refers to response group) to be able to reject the null 
21 
 
hypothesis that the failure rates for experimental and control subjects are equal with 
probability (power) 0.8. The Type 1 error probability associated with this test of this null 
hypothesis is 0.05.  An uncorrected chi-squared statistic was constructed to evaluate this null 
hypothesis. Therefore, the total sample size is 86; 43 for the resistant and response group. 
 
2.3 Flow of the study 
 
The CML patients were categorized into two groups, the CML-IM resistant labeled as 
“Resistant” (R) group and the CML-IM responsive labeled as “Good response” (G) group 
based on their response towards three monitoring parameters; cytogenetic, molecular and 
haematological. Commercial deoxyribonucleic acid (DNA) extraction kit, GeneAll Exgene 
Blood SV mini was used to extract genomic DNA from blood. Polymerase Chain Reaction 
(PCR) for PDGFRA on exon 12 and exon 18 were carried out to amplify the amplicons. To 
detect the presence of DNA fragments from PCR products, the products were loaded to 
agarose gel for electrophoresis and the stained gel was visualized under ultra violet (UV) 
transilluminator. This followed by purification of the amplicons using Illustra TM Exoprostar 
TM
 Enzymatic PCR and Sequencing Clean-Up. The purified PCR products then were sent to 
First Base Labarotory for DNA sequencing service. The sequencing results were screened by 
using Basic Local Alignment Search Tool (BLAST) software from National Center for 
Biotechnology Information (NCBI) by comparing with the sequence from the reference 
journal; Holtkamp et al., 2006. To the final touch, data from the results were converted by 
statistical analysis into the form of graphs and charts as shown in the Result chapter. The 
flow chart of the study is shown in Figure 2.1. 
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Figure 2.1   Flowchart of the study 
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2.4 Inclusion criteria 
 
IM-resistant CML patient included in this study was those; 
i. Confirmed clinically and hematologically to have CML with presence of Ph 
chromosome. 
ii. Undergone IM treatment (400 mg, 600 mg or 800mg dose) for at least 12 months 
iii. Experienced signs of primary or secondary resistance to the treatment. 
iv. Showed suboptimal response and failure to IM treatment at cytogenetic, 
hematological and molecular level (based on European LeukemiaNet 2013 (ELN) 
guidelines) (Baccarani et al., 2009). 
IM-responsive CML patient included in this study was those; 
i. Confirmed clinically and hematologically to have CML with presence of Ph 
chromosome. 
ii. Undergone IM treatment (400 mg, 600 mg or 800mg dose) for at least 12 months 
iii. Showed optimal response to IM treatment at cytogenetic, hematological and 
molecular level (based on ELN 2013 guidelines) (Baccarani et al., 2009). 
 
2.5 Exclusion criteria 
 
i. CML patients with absence of Ph chromosome confirmed by molecular test. 
ii. CML patients who were treated with IM but less than 12 months. 
iii. CML patients who are not treated with IM. 
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2.6 Methodology 
 
          2.6.1  Genomic DNA extraction 
 
Genomic DNA (gDNA) was extracted from the patient’s peripheral blood which was 
stored in EDTA tube using a commercial GeneAll Exgene Blood SV mini kit (GeneAll 
Biotechnology, Korea) according to manufacturer’s instruction. Included in this kit are 
GeneAll Proteinase K, Buffer CL, Buffer BL, Buffer BW, Buffer TW and Buffer AE. The 
protocol begins with 20 µl of Proteinase K solution was pipetted into the bottom of a 1.5 ml 
tube. This followed by 200 µl of blood from each sample was transferred to the tube and then 
200 µl of Buffer BL was pipetted into the same tube. The tube was vortexed for 15 seconds to 
mix it. The mixture was incubated at 56⁰C for 10 minutes using Thermomixer (Eppendorf, 
Germany) before being centrifuged briefly to remove any drops from internal lid wall. 
 
Next, 200 µl of absolute ethanol was added to the sample to precipitate the DNA. The 
tube was placed on pulse-vortex for 15 seconds to mix the samples thoroughly, and then 
centrifuged briefly for about 10 seconds. The mixture was transferred to the SV column 
carefully, followed by centrifugation at 8000 rpm for 1 minute to resuspend the cell pellet. 
The collection tube was then discarded and replaced with the new one. Next step was the 
addition of 600 µl of Buffer BW into each SV column and then was centrifuged for 1 minute 
at 8000 rpm. Once again, the collection tube was discarded and replaced with new collection 
tube. A volume of 700 µl of Buffer TW was added and subjected to 1 minute centrifugation 
at 6000 rpm. The pass-through was discarded and the SV column was reinserted back into the 
collection tube. Centrifugation was then done at full speed for 1 minute to remove residual 
